Recursion Pharmaceuticals ( RXRX ) Surges 8.2%: Is This an Indication of Further Gains?
Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Nvidia Has Invested in These 6 Companies. Should You Follow Suit?
The world's most valuable company holds stakes in a number of smaller tech players.
Where Will Recursion Pharmaceuticals Be in 5 Years?
Could investing in this stock be an underrated way to profit from the rapidly expanding AI industry?
The Biotech Stock That's Too Risky for Most Investors
It's unclear how long it's going to be before this company has a product to sell.
10 Hidden-Gem AI Stocks to Buy Right Now
From AI-powered insurance bots to drug discovery platforms, these overlooked stocks offer pure-play exposure to artificial intelligence without trillion-dollar valuations.
Jim Cramer Says This Financial Stock Is A 'Total Spec,' Likes Dutch Bros, - Dutch Bros ( NYSE:BROS ) , American Bitcoin ( NASDAQ:ABTC )
On CNBC's "Mad Money Lightning Round," Jim Cramer said he likes Dutch Bros ( NYSE: BROS ) . He recommended buying some now and then buying some of the stock in the $40s. On Sept. 24, RBC Capital analyst Logan Reich reiterated Dutch Bros with an Outperform and maintained a price target of $85.
Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now
BigBear.ai is bigger than both of these AI-focused companies now. That could change.
Recursion Pharmaceuticals ( RXRX ) Laps the Stock Market: Here's Why
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.98, representing a +1.32% change from its previous close.
Recursion Pharmaceuticals ( RXRX ) Stock Sinks As Market Gains: What You Should Know
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $4.77, signifying a -1.24% move from its prior day's close.
Nvidia Has $4.3 Billion Invested in These 6 Artificial Intelligence ( AI ) Stocks. Here's the Best of the Bunch.
Most of Nvidia's AI bets are riding on one stock.
Biodexa Moves Into Phase 3 With eRapa For FAP With First Patient Enrolled - Biodexa Pharmaceuticals ( NASDAQ:BDRX ) , Pfizer ( NYSE:PFE )
Reports Being On Track To Be First Mover In $7B Market With No Current Therapeutic Options
3 AI Stocks Disrupting Trillion-Dollar Industries
These three companies are using artificial intelligence (AI) to transform defense, pharmaceuticals, and banking.
If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today
This AI company isn't yet living up to the hype.
1 Monster Nvidia-Backed Artificial Intelligence ( AI ) Data Center Stock To Buy Hand Over Fist Before It Soars 20%, According to a Wall Street Analyst
Filings indicate that Nvidia holds an equity stake in a leading data center operation.
1 Reason to Buy This Beaten-Down Artificial Intelligence ( AI ) Stock, and 2 Reasons to Sell
There might be better artificial intelligence (AI) stocks out there to buy.
The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode
The artificial intelligence revolution is leaving no opportunity unaddressed.
Why Recursion Pharmaceuticals Stock Caught a Cold This Week
The few news items from and about the company weren't all that positive.
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
These companies are in the right place at the right time with the right products.
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.
Why Recursion Pharmaceuticals Stock Tanked on Tuesday
It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.
Recursion ( RXRX ) Q2 Revenue Jumps 33%
Recursion Pharmaceuticals ( NASDAQ:RXRX ) , a technology-driven biotech company decoding biology using artificial intelligence for drug discovery, released its financial results for the second quarter of 2025 on August 5, 2025.
Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates - Recursion Pharmaceuticals ( NASDAQ:RXRX )
Recursion reports second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million. Recursion reports a second-quarter loss of 41 cents per share, missing estimates for a loss of 34 cents per share. The market's back, and these 3 income stocks are thriving. See them here→
Recursion Pharmaceuticals ( RXRX ) Reports Q2 Loss, Beats Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -17.14% and +33.71%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.
2 Beaten-Down Stocks With Incredible Upside Potential
Getting in on the ground floor with these companies might lead to superior returns.
Gilead Sciences ( GILD ) Expected to Beat Earnings Estimates: Should You Buy?
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recursion Pharmaceuticals ( RXRX ) Registers a Bigger Fall Than the Market: Important Facts to Note
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $5.81, moving 2.35% from the previous trading session.
Why Recursion Pharmaceuticals ( RXRX ) Dipped More Than Broader Market Today
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.95, marking a -5.71% move from the previous day.
Why Recursion Pharmaceuticals Stock Got Mashed on Monday
Investors weren't cheered by news from one of the biotech's rivals.
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades.
You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save.
Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma - Recursion Pharmaceuticals ( NASDAQ:RXRX ) , Tempus AI ( NASDAQ:TEM ) , Palantir Technologies ( NASDAQ:PLTR )
Palantir, Tempus and Recursion are racing to reshape drug discovery with AI and data-driven platforms. Investors are watching closely as these disruptors challenge Big Pharma's traditional R&D with faster, smarter pipelines. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
Recursion Pharmaceuticals and Relay Therapeutics both leverage their respective AI drug discovery platforms to potentially develop novel therapeutic candidates.
Recursion Pharmaceuticals ( RXRX ) Stock Drops Despite Market Gains: Important Facts to Note
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $6.43, signifying a -1.68% move from its prior day's close.
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Top 2 Health Care Stocks You May Want To Dump This Quarter - Medpace Hldgs ( NASDAQ:MEDP ) , Recursion Pharmaceuticals ( NASDAQ:RXRX )
As of July 22, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices ...
Recursion Pharmaceuticals Options Trading: A Deep Dive into Market Sentiment - Recursion Pharmaceuticals ( NASDAQ:RXRX )
Investors with a lot of money to spend have taken a bearish stance on Recursion Pharmaceuticals RXRX. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
Is Recursion Pharmaceuticals Gaining or Losing Market Support? - Recursion Pharmaceuticals ( NASDAQ:RXRX )
Recursion Pharmaceuticals's RXRX short percent of float has fallen 8.79% since its last report. The company recently reported that it has 117.41 million shares sold short, which is 29.07% of all regular shares that are available for trading.
Why Is Recursion Pharma Stock Surging On Monday? - Recursion Pharmaceuticals ( NASDAQ:RXRX )
REC-3565, a MALT1 inhibitor developed via AI, is now in Phase 1 for blood cancers. REC-617 showed encouraging signs in a patient with recurrent ovarian cancer. A new wave of value and momentum stocks could be setting up for major moves-and Tim Melvin will name them live this Wednesday.
Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday - AbCellera Biologics ( NASDAQ:ABCL ) , Absci ( NASDAQ:ABSI )
U.S. stocks were higher, with the Dow Jones index gaining around 100 points on Monday. Shares of Galaxy Digital GLXY rose sharply during Monday's session after the company announced it has partnered with K Wave Media to accelerate Bitcoin treasury strategies and have access to greater ...
Recursion Pharmaceuticals ( RXRX ) Soars 5.8%: Is Further Upside Left in the Stock?
Recursion Pharmaceuticals (RXRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Recursion Pharmaceuticals ( RXRX ) Rises Higher Than Market: Key Facts
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $5.52, indicating a +2.41% shift from the previous trading day.
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock
RXRX gains 5.5% in a month on positive pipeline update. long-term hold advised given strong potential of its AI-driven drug discovery platform.
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.
Jensen Huang's Nvidia Owns 6 Stocks. Here's the Best of the Bunch.
Nvidia ( NASDAQ: NVDA ) is widely considered the ultimate pick-and-shovel play in the artificial intelligence ( AI ) space. The company's graphics processing units ( GPUs ) have become the standard for training the large language models ( LLMs ) that make AI possible.
Recursion Pharmaceuticals ( RXRX ) Surpasses Market Returns: Some Facts Worth Knowing
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.72, marking a +2.24% move from the previous day.
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program
Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.
10 Under-the-Radar Tech Stocks With Incredible Growth Potential
Just because it's not a household name doesn't mean it's not a magnificent investment.
Here's Why Shares in Recursion Pharmaceuticals Surged Today
Shares in biotech company Recursion Pharmaceuticals ( NASDAQ: RXRX ) surged by more than 12% by 11 a.m. ET today. The move is due to a de-risking event in its drug discovery pipeline.The de-risking event relates to the acquisition of the 50% interest in an ENPP1 inhibitor program ( REV102 ) that ...
Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Rallybio ( NASDAQ:RLYB ) , Recursion Pharmaceuticals ( NASDAQ:RXRX )
Rallybio receives $7.5 million upfront equity and is eligible for $17.5 million in future milestone payments. The cash runway is now extended into mid-2027 following the asset sale. From tariffs to inflation, macro risks are rising-Matt Maley reveals how he's trading it all, live this Wednesday ...
